Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Closed Loop Medicine Wants To Deliver Upon Its Name, Tailoring Drug Dosages

Executive Summary

The company is developing combination products that link software and therapeutics to personalize drug and care regimens.

You may also be interested in...



Minute Insight: BellaSeno Starts Trials Of Reconstructive Chest Implants Using Resorbable Material

The company is trialing absorbable implants for both cosmetic and reconstructive surgeries.

Medtech Monthly, Ep. 2: Where Does Diabetes Tech Stand In 2022?

In this edition of Medtech Monthly, Robert Gabbay, chief scientific and medical officer for the American Diabetes Association talked to Medtech Insight about diabetes tech, where it's headed, and what it could mean for preventative care.

Execs On The Move: Accuray, Acutus Promote New CEOS In July

An interactive view of medtech executive changes from the month of July 2022.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel